Unexpected results in the treatment of persistent Covid
Recently, the Fighting Infections Foundation, linked to Germans Trias Hospital, has published results that have surprised the medical community: plasmapheresis has not proven to be an effective solution to treating persistent COVID. This technique, which consists of cleaning the blood plasma, had been the subject of a clinical trial for three years with 50 patients.
Pax study design
The PAX study sought to perform a plasma replacement in patients with persistent Symptoms of COVID, eliminating inflammatory substances from the blood. Although plasmapheresis has shown promising results in other immune conditions, the results obtained in this study indicate that it is not useful for persistent COVID.
Process methodology
The participating patients were randomly divided into two groups: one who received plasmapheresis and another who received only physiological serum. The treatment included six plasmatic replacement sessions, followed by a clinical follow -up for 90 days to evaluate the health status of the participants.
Publication and reactions
The results have been published in the magazine ‘Nature Communications’, which has cataloged this study among the most prominent in its field. The director of the Persistent Covid program, Lourdes Mateu, expressed his disappointment in the face of the results, but emphasized the importance of these findings as a scientific test that helps to guide future treatments.
New perspectives in the treatment of COVID
In the meantime, the Foundation has started a new project, called ‘Thalassa’, to investigate the effectiveness of the plaitidepsin, an anticancer agent with anti -inflammatory properties. This study, which is carried out in collaboration with IRSI Caixa, includes a hundred adult patients with persistent COVID and seeks to offer new therapeutic solutions.
A future full of possibilities
Plitidepsin, developed by Pharmamar, has shown potential against several viruses, including Sars-COV-2. With their incorporation into the study, researchers hope to open new avenues in the treatment of persistent COVID, giving hope to those who fight against this disease.